BioSpace News Archive

Supernus Pharmaceuticals, Inc. announced that the Company’s management will present an overview and update, as well as host investor meetings, at the following virtual investor conferences in November 2020.

Kodiak Sciences Inc. announced that a pre-recorded presentation of clinical study data on its investigational therapy KSI-301 is available at the American Academy of Ophthalmology 2020 Virtual Annual Meeting.

Women’s Health Specialty Care, has enrolled their first patient in the VESAIR Clinical Trial. The VESAIR Clinical Trial is being conducted in several distinguished clinics throughout the US to test the safety and efficacy of the Vesair Bladder Control Balloon procedure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201111005115/en/ (Photo: Solace Th

University of Pennsylvania Medical Center, has enrolled their first patient in the VESAIR Clinical Trial. The Vesair Clinical Study is being conducted in several distinguished clinics throughout the US to test the safety and efficacy of the Vesair Bladder Control Balloon procedure.

Associate Urologists of North Carolina, has enrolled their first patient in the VESAIR Clinical Trial. The VESAIR Clinical Trial is being conducted in several distinguished clinics throughout the US to test the safety and efficacy of the Vesair Bladder Control Balloon procedure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201111005110/en/ Solace Thera

Vor Biopharma , an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, today announced an exclusive licensing agreement with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), for intellectual property related to a clinical-stage anti-CD33 chimeric antigen receptor T-cell (CAR-T) therapy candidate. This CAR-T construct was devised by T-

Caraway Therapeutics today announced that the Company is scheduled to present at two upcoming virtual conferences during November, 2020. Caraway’s Chief Executive Officer, Martin D. Williams, will present at the Stifel Virtual Healthcare Conference on November 18, 2020 at 8:40am ET. Caraway’s President and Chief Scientific Officer, Magdalene Moran, Ph.D., will present in two sessions at the Autophagy Showcas

Lineage Cell Therapeutics Completes Patient Enrollment in Phase 1/2a Clinical Study of OpRegen ® Cell Therapy for the Treatment of Dry Age-related Macular Degeneration OpRegen Data Update to be Featured in Presentation by Principal Investigator Christopher D. Riemann, M.D., at 2020 AAO Annual Meeting on November 15, 2020 Therapeutic Expert Call to Discuss Results Scheduled for November 17, 2020 CARLSBAD, Calif.--( BUSINESS WIRE )--

-Initial therapeutic pipeline to target liver diseases -5AM Ventures and Wu Capital join existing investors Frazier Healthcare Partners and Jubilant Biosys Limited

Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary intratumoral immunotherapy products to kill tumors and increase immune system recognition of cancers, today announced new efficacy and safety data from the ongoing Phase 1/2 clinical study of INT230-6, the Company’s lead product candidate.